Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

Please provide your email address to receive an email when new articles are posted on . People with cancer who received statins during immune checkpoint inhibitor therapy had improved prognosis.

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. Checkpoint ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Preexisting autoimmune diseases do not increase mortality risk in patients treated with immune ...

CHICAGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Best-in-Class PTRS, today announced compelling results from a new study demonstrating the ability ...

Black patients have longer time to treatment discontinuation, similar time to next treatment, slightly improved overall survival than White patients. (HealthDay News) — Black patients have similar ...

Crisis within a crisis: A CDC WONDER analysis of the pandemic's impact on cancer and cardiovascular mortality. Thromboembolic disease in breast cancer: Analysis of risk factors and outcomes from the ...

Adding pembrolizumab to docetaxel failed to improve survival in metastatic castration-resistant prostate cancer. Overall survival was 19-20 months regardless of treatment arm, even in patients with PD ...